Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis

BACKGROUND: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease-modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence coming mainly from Israel, Europe and North America using mRNA and adenoviral vecto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciampi, Ethel, Uribe-San-Martin, Reinaldo, Soler, Bernardita, García, Lorena, Guzman, Jorge, Pelayo, Carolina, Jürgensen, Lukas, Guzman, Ignacio, Vera, Francisco, Galleguillos, Lorna, Cárcamo, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842089/
https://www.ncbi.nlm.nih.gov/pubmed/35182880
http://dx.doi.org/10.1016/j.msard.2022.103690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842089/
https://www.ncbi.nlm.nih.gov/pubmed/35182880
http://dx.doi.org/10.1016/j.msard.2022.103690

Ejemplares similares